Assistant Professor of Medicine, University of Pittsburgh
My research interests lies in translational cancer immunotherapy and early-phase clinical trials. I am working with Dr. Zarour and Kirkwood to coordinate the clinical care and translational research of a novel trial combining PD-1 inhibitor Pembrolizumab with immunomodulatory PEG-IFN. I presented preliminary results at ASCO 2015. Final results have been collated along with correlative analyses and are pending publication.
More recently, in collaboration with Bristol-Myers Squibb and based on published findings by Dr Zarour’s laboratory, I have contributed to the development and implementation of a first-in-human study of TIGIT mAb (BMS-986207) singly and in combination with Nivolumab that is presently in active accrual and for which I am the institutional Principle Investigator. I am also the institutional Principle Investigator for first-in-human studies of GITR mAb (TRX-518), pegylated arginase (AEB1102) and IDO inhibitor (BMS-986205).
Based on emerging data implicating intestinal dysbiosis in mediating non-response to PD-1 blockade, I developed with Dr. Zarour a protocol evaluating fecal microbiota transplant in combination with PD-1 blockade to treat PD-1 non-responders. This first-in-human study was selected for funding by Merck to support the clinical costs and is IRB approved. In the context of this trial that I am the Principle Investigator for, I work in close collaboration with Dr. Zarour and co-investigators Drs. Methe and Benos, for the performance of the correlative studies in the context of the new clinical trial with fecal transplant microbiota and pembrolizumab in PD-1 refractory melanoma patients.
Clinical Interest
Could your gut microbes hinder your cancer treatment? A new first-in-human trial investigates
Aug 01, 2018 15:23 pm UTC| Insights & Views Health
Could the poop of some cancer patients hold the key to treating certain cancers in all people? What does cancer have to do with poop? In the past few years, researchers around the world, including us, have realized that...